Last updated 2026-07-26
- Raised $565k Series A led by European Innovation Council (EIC), Dec 2021
- Raised $4M grant, Dec 2020
- Raised $3M grant, Aug 2020
Total raised
$11.1M
Last: Undisclosed Round 2024-02
Stage
Series A
Founded
2015
Headcount
10
HQ
Jerusalem, Israel
Sector
Health Tech & Life Sciences
About
Betalin Therapeutics is a biotech company specializing in tissue engineering for curing diabetes. The company is developing an Engineered Micro Pancreas (EMP), a novel technology that aims to provide significant levels of glucose-regulated insulin secretion over extended periods. This approach uses a biological scaffold to support insulin-producing beta cells, mimicking their natural environment to ensure long-term survival and function, with the goal of eliminating the need for daily insulin injections for patients with Type 1 and severe Type 2 diabetes.
Funding history · 6 rounds · $11.1M total
2024-01
B Round
Undisclosed
★ Together We Invest
2021-12
A Round
$565K
★ European Innovation Council (EIC)
2020-12
Grant
$4.0M
2020-08
Grant
$3.0M
2019-03
Seed
$2.5M
2015-12
Grant
$1.0M
Headcount over time
From 11 (2018-07) to 12 (2026-07) · +1 (+9%) · 41 points · source: Finder history + radar grounding
Q&A
- What is Betalin Therapeutics' primary focus?
- Betalin Therapeutics is a biotech company specializing in tissue engineering for curing diabetes, developing an Engineered Micro Pancreas (EMP) to provide glucose-regulated insulin secretion.
- When was Betalin Therapeutics founded?
- Betalin Therapeutics was founded in 2015.
- What is the current employee count for Betalin Therapeutics?
- Betalin Therapeutics has 1-10 employees.
- What was Betalin Therapeutics' most recent funding round?
- In February 2024, Betalin Therapeutics received a grant from Together We Invest.
- What was Betalin Therapeutics' most recent equity funding round?
- In February 2022, Betalin Therapeutics closed an A Round, with the.
- What is the total amount of funding Betalin Therapeutics has raised to date?
- Betalin Therapeutics has raised a total of $15,100,285 USD.
- What is the product stage of Betalin Therapeutics' technology?
- Betalin Therapeutics' product is currently in the clinical trial stage.
- Who are the co-founders of Betalin Therapeutics?
- The co-founders of Betalin Therapeutics are Shuki Joshua Hershcovich, Shay Hershcovich, and Eduardo Mitrani.
Team · 3
Shuki Joshua Hershcovich
Founder · Co-Founder
Shay Hershcovich
Founder · Co-Founder
Eduardo Mitrani
Founder · Inventor and Founder
Sectors & technology
Primary sector
Health Tech & Life Sciences
Sub-sectors
Health Tech & Life SciencesPharma & Medical BiotechnologyBiomaterials & Tissue Engineering
Technologies
Materials & SubstancesImplantsBiologicalsCells
Target customers
Healthcare & Life SciencesHealthcareProvidersPatients
Business model
B2B2C
Highlights
1 PatentsVerified
Tags
bioconvergencediabetescell-therapybiological-therapyregenerative-medicinebiopharmaceuticalbiotechnologychronic-patientstreatments
Full data — links, identifiers, deals & radar signals (jobs, patents, research, more)
External links
| Website | betalintherapeutics.com |
|---|---|
| linkedin.com/company/10782073 | |
| facebook.com/Betalin.Therapeutics.Inc | |
| YouTube | youtube.com/channel/UCvGtq0FUKMyK6n0s1F4jZrA |
Identifiers & details
| Founded | 2015 |
|---|---|
| Employees (exact) | 10 |
| Offices | Ramat Gan |
Radar intelligence
Patents
| EPO | 2 |
|---|
Web history (Wayback)
| Domain | betalintherapeutics.com |
|---|
Certificate / subdomain footprint
| Subdomains | 3 |
|---|
Israeli Companies Registrar (רשם החברות / ICA)
| Registrar # (ח.פ.) | 515274272 |
|---|---|
| Status | פעילה |
| Corp type | ישראלית חברה פרטית |
| Incorporated | 2015-07-28 |
| Purpose | לעסוק בכל עיסוק חוקי |
| Liability | מוגבלת |
| In violation (unfiled) | no |
| Last annual report | 2026 |
| Active charges / liens | 0 |
| Registry events | 5 — other (1), shares_capital (1), annual_report (3) |
| Registered address | דרך מן קלמן 0 ירושלים |
Recent registry events
| Date | Event |
|---|---|
| 2025-08-28 | שינוי בתקנון |
| 2025-08-24 | הקצאת מניות |
| 2026-07-13 | דו~ח שנתי-הסרת בעל תפקיד |
| 2026-07-13 | דו~ח שנתי-הסרת דירקטור |
| 2026-07-13 | דו~ח שנתי-הוספת דירקטור |